Delivery Order SPE2DB20D3103-SPE2DB22FM4Q2
- Not listed
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Renflexis 100 mg vials. The contract has a ceiling value of $6,529.60 and runs through November 24, 2023. It is a firm fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Renflexis 100 mg vials. The contract has a ceiling value of $6,284.32 and an ultimate completion date of April 20, 2023. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Renflexis 100 mg vials, a pharmaceutical product, with a ceiling value of $7,244.28 and a period of performance through April 2025. The contract is not set aside and was competitively awarded. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $35,093.08, is for the delivery of Renflexis 100 mg vials. It is a firm fixed-price contract with an ultimate completion date of April 16, 2025. The contract is not set aside and is open to full and open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Renflexis 100 mg vials. The contract is a firm fixed-price delivery order with a ceiling value of $8,516.00 and a period of performance through April 30, 2025. Amerisourcebergen Drug Corp is the prime contractor, and there is no set-aside designation indicated. This order is part of a larger Indefinite Delivery Contract (IDC) held by...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Renflexis 100 mg vials, with a ceiling value of $14,078.68 and an ultimate completion date of July 14, 2025. The contract is a Firm Fixed Price Delivery Order, without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide 100 mg vials of the medication Renflexis. The contract has a ceiling value of $10,392.66 and a period of performance through July 2, 2025. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive pharmaceutical support vehicle for...
- This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Renflexis 100 mg vials, a medication, with a ceiling value of $3,727.50 and a period of performance through April 18, 2025. The contract is not set aside and was awarded on April 17, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RENFLEXIS 100MG VL 1S, a pharmaceutical product. The contract has a firm fixed price, with a ceiling value of $12,472.21, and an ultimate completion date of July 7, 2025. The contract is not set aside and is open to competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp's Corporate Office Division. The contract, valued at $10,907.52, is for the supply of the pharmaceutical product Renflexis 100 mg vials. The ultimate completion date is July 22, 2024. This delivery order is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB22FM4Q2Delivery Order
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Renflexis 100 mg vials. The contract has a ceiling value of $3,941.28 and a completion date of January 31, 2022. It is a firm fixed-price contract without any set-aside designation, indicating full and open competition. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 1/28/22 |